Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4541016
Max Phase: Preclinical
Molecular Formula: C26H35ClN2O5
Molecular Weight: 491.03
Molecule Type: Unknown
Associated Items:
ID: ALA4541016
Max Phase: Preclinical
Molecular Formula: C26H35ClN2O5
Molecular Weight: 491.03
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccc(OCCN2CCCCC2)c(Cl)c1
Standard InChI: InChI=1S/C26H35ClN2O5/c1-5-32-25(30)22-17(3)28-18(4)23(26(31)33-6-2)24(22)19-10-11-21(20(27)16-19)34-15-14-29-12-8-7-9-13-29/h10-11,16,24,28H,5-9,12-15H2,1-4H3
Standard InChI Key: DLRCMYPWZNEWKB-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 491.03 | Molecular Weight (Monoisotopic): 490.2234 | AlogP: 4.57 | #Rotatable Bonds: 9 |
Polar Surface Area: 77.10 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 7.92 | CX LogP: 3.90 | CX LogD: 3.27 |
Aromatic Rings: 1 | Heavy Atoms: 34 | QED Weighted: 0.51 | Np Likeness Score: -0.96 |
1. Malek R, Arribas RL, Palomino-Antolin A, Totoson P, Demougeot C, Kobrlova T, Soukup O, Iriepa I, Moraleda I, Diez-Iriepa D, Godyń J, Panek D, Malawska B, Głuch-Lutwin M, Mordyl B, Siwek A, Chabchoub F, Marco-Contelles J, Kiec-Kononowicz K, Egea J, de Los Ríos C, Ismaili L.. (2019) New Dual Small Molecules for Alzheimer's Disease Therapy Combining Histamine H3 Receptor (H3R) Antagonism and Calcium Channels Blockade with Additional Cholinesterase Inhibition., 62 (24): [PMID:31724859] [10.1021/acs.jmedchem.9b00937] |
Source(1):